File this under better late than never, the visual abstract for last night and tonight's #NephJC is here!
Thiazide induced hyponatremia is this week's version of spooky sodium. Here's the visual abstract.
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
File this under better late than never, the visual abstract for last night and tonight's #NephJC is here!
Thiazide induced hyponatremia is this week's version of spooky sodium. Here's the visual abstract.
The recent CJASN data from DOPPS, also links to two excellent videos from the NHS Heart of England centre. They are a first person account, giving a vivid example of the change that simple itching can have in all aspects of day to day life.
The Visual Abstract for the ACTIVE trial NephJC, scheduled for Tuesday/Wednesday this week. From the Visual Abstract artist, @KidneyBea_n
Apart from the storify and transcript, don't miss the commentary from Rodby, and this summary from Paul Welling:
#nephjc A few final thoughts: pic.twitter.com/XdUZK1Z5K0
— Paul A Welling (@PaulAWelling1) June 7, 2017
Thanks again to the ISPD, PDI and Daniel Schwartz from ISPD/Vancouver for setting this up & publicizing